News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synageva BioPharma (GEVA) Announces Six-Month Data From Extension Study of SBC-102 (sebelipase alfa) in Late Onset LAL Deficiency at the American Association for Study of Liver Diseases Annual Meeting


11/12/2012 9:26:29 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced six month results from an ongoing extension study of sebelipase alfa in adults with late onset Lysosomal Acid Lipase (LAL) Deficiency at the American Association for the Study of Liver Diseases (AASLD) annual meeting being held in Boston, MA, November 9-13, 2012.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES